ID   VIP1_HUMAN              Reviewed;        1433 AA.
AC   Q6PFW1; O15082; Q5HYF8; Q7Z3A7; Q86TE7; Q86UV3; Q86UV4; Q86XW8;
AC   Q8IZN0;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   10-MAY-2017, entry version 122.
DE   RecName: Full=Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1;
DE            EC=2.7.4.21;
DE            EC=2.7.4.24;
DE   AltName: Full=Diphosphoinositol pentakisphosphate kinase 1;
DE   AltName: Full=Histidine acid phosphatase domain-containing protein 2A;
DE   AltName: Full=IP6 kinase;
DE   AltName: Full=Inositol pyrophosphate synthase 1;
DE   AltName: Full=InsP6 and PP-IP5 kinase 1;
DE   AltName: Full=VIP1 homolog;
DE            Short=hsVIP1;
GN   Name=PPIP5K1; Synonyms=HISPPD2A, IP6K, IPS1, KIAA0377, VIP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 5).
RC   TISSUE=Bone marrow, Testis, and Trachea;
RX   PubMed=12825070; DOI=10.1038/sj.ejhg.5200991;
RA   Avidan N., Tamary H., Dgany O., Cattan D., Pariente A., Thulliez M.,
RA   Borot N., Moati L., Barthelme A., Shalmon L., Krasnov T.,
RA   Ben-Asher E., Olender T., Khen M., Yaniv I., Zaizov R., Shalev H.,
RA   Delaunay J., Fellous M., Lancet D., Beckmann J.S.;
RT   "CATSPER2, a human autosomal nonsyndromic male infertility gene.";
RL   Eur. J. Hum. Genet. 11:497-502(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7).
RC   TISSUE=Brain;
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [3]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R., Nomura N.;
RL   Submitted (JUL-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Endometrial adenocarcinoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 6).
RC   TISSUE=Eye, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [7]
RP   FUNCTION, ENZYME ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17690096; DOI=10.1074/jbc.M704656200;
RA   Fridy P.C., Otto J.C., Dollins D.E., York J.D.;
RT   "Cloning and characterization of two human VIP1-like inositol
RT   hexakisphosphate and diphosphoinositol pentakisphosphate kinases.";
RL   J. Biol. Chem. 282:30754-30762(2007).
RN   [8]
RP   FUNCTION, ENZYME ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=17702752; DOI=10.1074/jbc.M704655200;
RA   Choi J.H., Williams J., Cho J., Falck J.R., Shears S.B.;
RT   "Purification, sequencing, and molecular identification of a mammalian
RT   PP-InsP5 kinase that is activated when cells are exposed to
RT   hyperosmotic stress.";
RL   J. Biol. Chem. 282:30763-30775(2007).
RN   [9]
RP   FUNCTION, AND ENZYME ACTIVITY.
RX   PubMed=17412958; DOI=10.1126/science.1139099;
RA   Mulugu S., Bai W., Fridy P.C., Bastidas R.J., Otto J.C., Dollins D.E.,
RA   Haystead T.A., Ribeiro A.A., York J.D.;
RT   "A conserved family of enzymes that phosphorylate inositol
RT   hexakisphosphate.";
RL   Science 316:106-109(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1152, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   CATALYTIC ACTIVITY.
RX   PubMed=18981179; DOI=10.1074/jbc.M805686200;
RA   Lin H., Fridy P.C., Ribeiro A.A., Choi J.H., Barma D.K., Vogel G.,
RA   Falck J.R., Shears S.B., York J.D., Mayr G.W.;
RT   "Structural analysis and detection of biological inositol
RT   pyrophosphates reveal that the family of VIP/diphosphoinositol
RT   pentakisphosphate kinases are 1/3-kinases.";
RL   J. Biol. Chem. 284:1863-1872(2009).
RN   [14]
RP   BIOPHYSICOCHEMICAL PROPERTIES, CATALYTIC ACTIVITY, SUBCELLULAR
RP   LOCATION, POLYPHOSPHOINOSITIDE-BINDING DOMAIN, AND MUTAGENESIS OF
RP   ARG-399 AND ARG-417.
RX   PubMed=21222653; DOI=10.1042/BJ20101437;
RA   Gokhale N.A., Zaremba A., Shears S.B.;
RT   "Receptor-dependent compartmentalization of PPIP5K1, a kinase with a
RT   cryptic polyphosphoinositide binding domain.";
RL   Biochem. J. 434:415-426(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-944; SER-987; SER-1037;
RP   SER-1073 AND SER-1152, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-944, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Bifunctional inositol kinase that acts in concert with
CC       the IP6K kinases IP6K1, IP6K2 and IP6K3 to synthesize the
CC       diphosphate group-containing inositol pyrophosphates
CC       diphosphoinositol pentakisphosphate, PP-InsP5, and bis-
CC       diphosphoinositol tetrakisphosphate, (PP)2-InsP4. PP-InsP5 and
CC       (PP)2-InsP4, also respectively called InsP7 and InsP8, regulate a
CC       variety of cellular processes, including apoptosis, vesicle
CC       trafficking, cytoskeletal dynamics, exocytosis, insulin signaling
CC       and neutrophil activation. Phosphorylates inositol
CC       hexakisphosphate (InsP6) at positions 1 or 3 to produce PP-InsP5
CC       which is in turn phosphorylated by IP6Ks to produce (PP)2-InsP4.
CC       Alternatively, phosphorylates at position 1 or 3 PP-InsP5,
CC       produced by IP6Ks from InsP6, to produce (PP)2-InsP4. Activated
CC       when cells are exposed to hyperosmotic stress.
CC       {ECO:0000269|PubMed:17412958, ECO:0000269|PubMed:17690096,
CC       ECO:0000269|PubMed:17702752}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1D-myo-inositol hexakisphosphate = ADP +
CC       1D-myo-inositol 5-diphosphate 1,2,3,4,6-pentakisphosphate.
CC   -!- CATALYTIC ACTIVITY: ATP + 1D-myo-inositol 1-diphosphate 2,3,4,5,6-
CC       pentakisphosphate = ADP + 1D-myo-inositol 1,5-bis(diphosphate)
CC       2,3,4,6-tetrakisphosphate.
CC   -!- CATALYTIC ACTIVITY: ATP + 1D-myo-inositol 5-diphosphate 1,2,3,4,6-
CC       pentakisphosphate = ADP + 1D-myo-inositol 1,5-bis(diphosphate)
CC       2,3,4,6-tetrakisphosphate.
CC   -!- CATALYTIC ACTIVITY: ATP + 1D-myo-inositol hexakisphosphate = ADP +
CC       1D-myo-inositol 1-diphosphate 2,3,4,5,6-pentakisphosphate.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.12 uM for InsP6 {ECO:0000269|PubMed:17690096,
CC         ECO:0000269|PubMed:17702752, ECO:0000269|PubMed:21222653};
CC         KM=0.10 uM for InsP7 {ECO:0000269|PubMed:17690096,
CC         ECO:0000269|PubMed:17702752, ECO:0000269|PubMed:21222653};
CC         Vmax=0.03 nmol/min/mg enzyme with InsP6 as substrate
CC         {ECO:0000269|PubMed:17690096, ECO:0000269|PubMed:17702752,
CC         ECO:0000269|PubMed:21222653};
CC         Vmax=0.13 nmol/min/mg enzyme with InsP7 as substrate
CC         {ECO:0000269|PubMed:17690096, ECO:0000269|PubMed:17702752,
CC         ECO:0000269|PubMed:21222653};
CC         Note=The catalytic efficiency is 80 folds higher for 5-PP-InsP5
CC         (InsP7) compared to InsP6.;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:17690096, ECO:0000269|PubMed:17702752,
CC       ECO:0000269|PubMed:21222653}. Cell membrane
CC       {ECO:0000269|PubMed:21222653}. Note=Relocalizes to the plasma
CC       membrane upon activation of the PtdIns 3-kinase pathway.
CC       {ECO:0000269|PubMed:21222653}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1;
CC         IsoId=Q6PFW1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6PFW1-2; Sequence=VSP_030618, VSP_030622;
CC       Name=3;
CC         IsoId=Q6PFW1-3; Sequence=VSP_030618, VSP_030621;
CC       Name=4;
CC         IsoId=Q6PFW1-4; Sequence=VSP_030615, VSP_030618, VSP_030621;
CC       Name=5;
CC         IsoId=Q6PFW1-5; Sequence=VSP_030616, VSP_030619, VSP_030623;
CC       Name=6;
CC         IsoId=Q6PFW1-6; Sequence=VSP_030617;
CC         Note=No experimental confirmation available.;
CC       Name=7;
CC         IsoId=Q6PFW1-7; Sequence=VSP_030618, VSP_030620, VSP_030624;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with a higher expression in
CC       skeletal muscle, heart and brain. {ECO:0000269|PubMed:17690096}.
CC   -!- DOMAIN: The C-terminal acid phosphatase-like domain binds
CC       PtdIns(3,4,5)P3 and InsP6. Despite its similarity with the
CC       phosphatase domain of histidine acid phosphatases, it has no
CC       phosphatase activity. {ECO:0000269|PubMed:21222653}.
CC   -!- SIMILARITY: Belongs to the histidine acid phosphatase family. VIP1
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA20831.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF502586; AAP30842.1; -; mRNA.
DR   EMBL; AF502587; AAP30843.1; -; mRNA.
DR   EMBL; AF502588; AAP30844.1; -; mRNA.
DR   EMBL; AF502589; AAP30845.1; -; mRNA.
DR   EMBL; AF543190; AAN40768.1; -; mRNA.
DR   EMBL; AB002375; BAA20831.2; ALT_INIT; mRNA.
DR   EMBL; BX538022; CAD97968.1; -; mRNA.
DR   EMBL; BX647814; CAI46011.1; -; mRNA.
DR   EMBL; BC050263; AAH50263.1; -; mRNA.
DR   EMBL; BC057395; AAH57395.1; -; mRNA.
DR   CCDS; CCDS32215.1; -. [Q6PFW1-3]
DR   CCDS; CCDS45252.1; -. [Q6PFW1-1]
DR   CCDS; CCDS53937.1; -. [Q6PFW1-7]
DR   RefSeq; NP_001124330.1; NM_001130858.2. [Q6PFW1-1]
DR   RefSeq; NP_001124331.1; NM_001130859.2. [Q6PFW1-3]
DR   RefSeq; NP_001177143.1; NM_001190214.1. [Q6PFW1-7]
DR   RefSeq; NP_055474.3; NM_014659.5. [Q6PFW1-3]
DR   RefSeq; XP_005254861.1; XM_005254804.1. [Q6PFW1-3]
DR   RefSeq; XP_016878237.1; XM_017022748.1. [Q6PFW1-3]
DR   RefSeq; XP_016878238.1; XM_017022749.1. [Q6PFW1-3]
DR   RefSeq; XP_016878239.1; XM_017022750.1. [Q6PFW1-3]
DR   RefSeq; XP_016878240.1; XM_017022751.1. [Q6PFW1-3]
DR   RefSeq; XP_016878248.1; XM_017022759.1. [Q6PFW1-6]
DR   UniGene; Hs.156814; -.
DR   UniGene; Hs.679105; -.
DR   UniGene; Hs.679911; -.
DR   ProteinModelPortal; Q6PFW1; -.
DR   SMR; Q6PFW1; -.
DR   BioGrid; 115031; 10.
DR   STRING; 9606.ENSP00000380129; -.
DR   ChEMBL; CHEMBL5046; -.
DR   iPTMnet; Q6PFW1; -.
DR   PhosphoSitePlus; Q6PFW1; -.
DR   BioMuta; PPIP5K1; -.
DR   DMDM; 74758334; -.
DR   EPD; Q6PFW1; -.
DR   MaxQB; Q6PFW1; -.
DR   PaxDb; Q6PFW1; -.
DR   PeptideAtlas; Q6PFW1; -.
DR   PRIDE; Q6PFW1; -.
DR   Ensembl; ENST00000334933; ENSP00000334779; ENSG00000168781. [Q6PFW1-3]
DR   Ensembl; ENST00000348806; ENSP00000308773; ENSG00000168781. [Q6PFW1-7]
DR   Ensembl; ENST00000360135; ENSP00000353253; ENSG00000168781. [Q6PFW1-7]
DR   Ensembl; ENST00000360301; ENSP00000353446; ENSG00000168781. [Q6PFW1-3]
DR   Ensembl; ENST00000396923; ENSP00000380129; ENSG00000168781. [Q6PFW1-1]
DR   Ensembl; ENST00000420765; ENSP00000400887; ENSG00000168781. [Q6PFW1-1]
DR   GeneID; 9677; -.
DR   KEGG; hsa:9677; -.
DR   UCSC; uc001zrw.3; human. [Q6PFW1-1]
DR   CTD; 9677; -.
DR   DisGeNET; 9677; -.
DR   GeneCards; PPIP5K1; -.
DR   H-InvDB; HIX0012186; -.
DR   HGNC; HGNC:29023; PPIP5K1.
DR   HPA; HPA039380; -.
DR   MIM; 610979; gene.
DR   neXtProt; NX_Q6PFW1; -.
DR   OpenTargets; ENSG00000168781; -.
DR   PharmGKB; PA165479401; -.
DR   eggNOG; KOG1057; Eukaryota.
DR   eggNOG; ENOG410XNSN; LUCA.
DR   GeneTree; ENSGT00390000009048; -.
DR   HOVERGEN; HBG108657; -.
DR   InParanoid; Q6PFW1; -.
DR   KO; K13024; -.
DR   OMA; MHSNQAS; -.
DR   OrthoDB; EOG091G00ZU; -.
DR   PhylomeDB; Q6PFW1; -.
DR   TreeFam; TF313594; -.
DR   BioCyc; MetaCyc:HS09822-MONOMER; -.
DR   BRENDA; 2.7.4.24; 2681.
DR   Reactome; R-HSA-1855167; Synthesis of pyrophosphates in the cytosol.
DR   GenomeRNAi; 9677; -.
DR   PRO; PR:Q6PFW1; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000168781; -.
DR   ExpressionAtlas; Q6PFW1; baseline and differential.
DR   Genevisible; Q6PFW1; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0003993; F:acid phosphatase activity; IEA:InterPro.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0033857; F:diphosphoinositol-pentakisphosphate kinase activity; IDA:UniProtKB.
DR   GO; GO:0000829; F:inositol heptakisphosphate kinase activity; IBA:GO_Central.
DR   GO; GO:0052723; F:inositol hexakisphosphate 1-kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0052724; F:inositol hexakisphosphate 3-kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0000832; F:inositol hexakisphosphate 5-kinase activity; IDA:UniProtKB.
DR   GO; GO:0000828; F:inositol hexakisphosphate kinase activity; IDA:MGI.
DR   GO; GO:0000827; F:inositol-1,3,4,5,6-pentakisphosphate kinase activity; IDA:UniProtKB.
DR   GO; GO:0006020; P:inositol metabolic process; IDA:UniProtKB.
DR   GO; GO:0032958; P:inositol phosphate biosynthetic process; IBA:GO_Central.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   CDD; cd07061; HP_HAP_like; 1.
DR   Gene3D; 3.40.50.1240; -; 1.
DR   InterPro; IPR033379; Acid_Pase_AS.
DR   InterPro; IPR000560; His_Pase_clade-2.
DR   InterPro; IPR029033; His_PPase_superfam.
DR   InterPro; IPR030138; PPIP5K1.
DR   PANTHER; PTHR12750:SF15; PTHR12750:SF15; 1.
DR   Pfam; PF00328; His_Phos_2; 1.
DR   SUPFAM; SSF53254; SSF53254; 3.
DR   PROSITE; PS00616; HIS_ACID_PHOSPHAT_1; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Cytoplasm; Kinase; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Transferase.
FT   CHAIN         1   1433       Inositol hexakisphosphate and
FT                                diphosphoinositol-pentakisphosphate
FT                                kinase 1.
FT                                /FTId=PRO_0000315688.
FT   NP_BIND     248    251       ATP. {ECO:0000250|UniProtKB:O43314}.
FT   NP_BIND     257    259       ATP. {ECO:0000250|UniProtKB:O43314}.
FT   NP_BIND     332    334       ATP. {ECO:0000250|UniProtKB:O43314}.
FT   REGION       64     65       Substrate binding.
FT                                {ECO:0000250|UniProtKB:O43314}.
FT   REGION      224    225       Substrate binding.
FT                                {ECO:0000250|UniProtKB:O43314}.
FT   REGION      337    340       Substrate binding.
FT                                {ECO:0000250|UniProtKB:O43314}.
FT   REGION      382    453       Polyphosphoinositide-binding domain.
FT                                {ECO:0000269|PubMed:21222653}.
FT   BINDING     145    145       ATP. {ECO:0000250|UniProtKB:O43314}.
FT   BINDING     198    198       ATP. {ECO:0000250|UniProtKB:O43314}.
FT   BINDING     205    205       ATP. {ECO:0000250|UniProtKB:O43314}.
FT   BINDING     224    224       ATP. {ECO:0000250|UniProtKB:O43314}.
FT   BINDING     259    259       Substrate.
FT                                {ECO:0000250|UniProtKB:O43314}.
FT   BINDING     273    273       Substrate.
FT                                {ECO:0000250|UniProtKB:O43314}.
FT   BINDING     275    275       ATP. {ECO:0000250|UniProtKB:O43314}.
FT   BINDING     320    320       ATP. {ECO:0000250|UniProtKB:O43314}.
FT   MOD_RES     944    944       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     987    987       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1037   1037       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1073   1073       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1145   1145       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:A2ARP1}.
FT   MOD_RES    1152   1152       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     653    653       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_030615.
FT   VAR_SEQ     810    821       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:12825070}.
FT                                /FTId=VSP_030616.
FT   VAR_SEQ     818   1433       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_030617.
FT   VAR_SEQ     818    821       Missing (in isoform 2, isoform 3, isoform
FT                                4 and isoform 7).
FT                                {ECO:0000303|PubMed:12825070,
FT                                ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|PubMed:9205841}.
FT                                /FTId=VSP_030618.
FT   VAR_SEQ     865    957       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:12825070}.
FT                                /FTId=VSP_030619.
FT   VAR_SEQ    1020   1082       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:9205841}.
FT                                /FTId=VSP_030620.
FT   VAR_SEQ    1062   1082       Missing (in isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:12825070,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_030621.
FT   VAR_SEQ    1082   1082       N -> NG (in isoform 2).
FT                                {ECO:0000303|PubMed:12825070}.
FT                                /FTId=VSP_030622.
FT   VAR_SEQ    1107   1240       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:12825070}.
FT                                /FTId=VSP_030623.
FT   VAR_SEQ    1167   1167       Y -> LETRFCHVGQAGLELLTSSDLPASASQSAGITGVSH
FT                                RTQPD (in isoform 7).
FT                                {ECO:0000303|PubMed:9205841}.
FT                                /FTId=VSP_030624.
FT   MUTAGEN     399    399       R->A: Decreases 8-fold the affinity for
FT                                PtdIns(3,4,5)P3.
FT                                {ECO:0000269|PubMed:21222653}.
FT   MUTAGEN     417    417       R->A: Decreases 16-fold the affinity for
FT                                PtdIns(3,4,5)P3.
FT                                {ECO:0000269|PubMed:21222653}.
FT   CONFLICT     44     44       D -> G (in Ref. 4; CAD97968).
FT                                {ECO:0000305}.
FT   CONFLICT    304    304       V -> M (in Ref. 4; CAD97968).
FT                                {ECO:0000305}.
FT   CONFLICT    374    374       E -> V (in Ref. 4; CAD97968).
FT                                {ECO:0000305}.
FT   CONFLICT    423    423       E -> Q (in Ref. 1; AAP30843/AAP30845/
FT                                AAN40768). {ECO:0000305}.
FT   CONFLICT    473    473       L -> P (in Ref. 4; CAD97968).
FT                                {ECO:0000305}.
FT   CONFLICT    483    483       F -> S (in Ref. 1; AAP30845/AAN40768).
FT                                {ECO:0000305}.
FT   CONFLICT    490    490       V -> E (in Ref. 4; CAD97968).
FT                                {ECO:0000305}.
FT   CONFLICT    548    548       G -> V (in Ref. 4; CAD97968).
FT                                {ECO:0000305}.
FT   CONFLICT    738    738       I -> L (in Ref. 1; AAP30845/AAN40768).
FT                                {ECO:0000305}.
FT   CONFLICT    788    788       V -> A (in Ref. 1; AAP30845/AAN40768).
FT                                {ECO:0000305}.
FT   CONFLICT    936    936       E -> G (in Ref. 4; CAI46011).
FT                                {ECO:0000305}.
FT   CONFLICT    985    985       A -> V (in Ref. 1; AAP30845/AAN40768).
FT                                {ECO:0000305}.
FT   CONFLICT   1020   1020       G -> A (in Ref. 1; AAP30843).
FT                                {ECO:0000305}.
FT   CONFLICT   1041   1041       L -> P (in Ref. 1; AAP30845/AAN40768).
FT                                {ECO:0000305}.
FT   CONFLICT   1066   1066       V -> L (in Ref. 1; AAP30842).
FT                                {ECO:0000305}.
FT   CONFLICT   1126   1126       A -> T (in Ref. 4; CAI46011).
FT                                {ECO:0000305}.
FT   CONFLICT   1134   1134       M -> V (in Ref. 4; CAI46011).
FT                                {ECO:0000305}.
FT   CONFLICT   1198   1198       P -> R (in Ref. 4; CAI46011).
FT                                {ECO:0000305}.
FT   CONFLICT   1293   1293       H -> M (in Ref. 1; AAP30845/AAN40768).
FT                                {ECO:0000305}.
FT   CONFLICT   1294   1294       D -> T (in Ref. 1; AAP30845/AAN40768).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1433 AA;  159521 MW;  BA0DEFB2A71B1467 CRC64;
     MWSLTASEGE STTAHFFLGA GDEGLGTRGI GMRPEESDSE LLEDEEDEVP PEPQIIVGIC
     AMTKKSKSKP MTQILERLCR FDYLTVVILG EDVILNEPVE NWPSCHCLIS FHSKGFPLDK
     AVAYSKLRNP FLINDLAMQY YIQDRREVYR ILQEEGIDLP RYAVLNRDPA RPEECNLIEG
     EDQVEVNGAV FPKPFVEKPV SAEDHNVYIY YPSSAGGGSQ RLFRKIGSRS SVYSPESSVR
     KTGSYIYEEF MPTDGTDVKV YTVGPDYAHA EARKSPALDG KVERDSEGKE IRYPVMLTAM
     EKLVARKVCV AFKQTVCGFD LLRANGHSFV CDVNGFSFVK NSMKYYDDCA KILGNTIMRE
     LAPQFQIPWS IPTEAEDIPI VPTTSGTMME LRCVIAIIRH GDRTPKQKMK MEVKHPRFFA
     LFEKHGGYKT GKLKLKRPEQ LQEVLDITRL LLAELEKEPG GEIEEKTGKL EQLKSVLEMY
     GHFSGINRKV QLTYYPHGVK ASNEGQDPQR ETLAPSLLLV LKWGGELTPA GRVQAEELGR
     AFRCMYPGGQ GDYAGFPGCG LLRLHSTFRH DLKIYASDEG RVQMTAAAFA KGLLALEGEL
     TPILVQMVKS ANMNGLLDSD GDSLSSCQHR VKARLHHILQ QDAPFGPEDY DQLAPTRSTS
     LLNSMTIIQN PVKVCDQVFA LIENLTHQIR ERMQDPRSVD LQLYHSETLE LMLQRWSKLE
     RDFRQKSGRY DISKIPDIYD CVKYDVQHNG SLGLQGTAEL LRLSKALADV VIPQEYGISR
     EEKLEIAVGF CLPLLRKILL DLQRTHEDES VNKLHPLCYL RYSRGVLSPG RHVRTRLYFT
     SESHVHSLLS VFRYGGLLDE TQDAQWQRAL DYLSAISELN YMTQIVIMLY EDNTQDPLSE
     ERFHVELHFS PGVKGVEEEG SAPAGCGFRP ASSENEEMKT NQGSMENLCP GKASDEPDRA
     LQTSPQPPEG PGLPRRSPLI RNRKAGSMEV LSETSSSRPG GYRLFSSSRP PTEMKQSGLG
     SQCTGLFSTT VLGGSSSAPN LQDYARSHGK KLPPASLKHR DELLFVPAVK RFSVSFAKHP
     TNGFEGCSMV PTIYPLETLH NALSLRQVSE FLSRVCQRHT DAQAQASAAL FDSMHSSQAS
     DNPFSPPRTL HSPPLQLQQR SEKPPWYSSG PSSTVSSAGP SSPTTVDGNS QFGFSDQPSL
     NSHVAEEHQG LGLLQETPGS GAQELSIEGE QELFEPNQSP QVPPMETSQP YEEVSQPCQE
     VPDISQPCQD ISEALSQPCQ KVPDISQQCQ ENHDNGNHTC QEVPHISQPC QKSSQLCQKV
     SEEVCQLCLE NSEEVSQPCQ GVSVEVGKLV HKFHVGVGSL VQETLVEVGS PAEEIPEEVI
     QPYQEFSVEV GRLAQETSAI NLLSQGIPEI DKPSQEFPEE IDLQAQEVPE EIN
//
